VR Advisory Services’s Aspire Biopharma Warrant ASBPW Stock Holding History

VR Advisory Services’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.66K	Hold	99,692	–	–	﹤0.01%	40
2025 Q4	$1.65K	Hold	99,692	–	–	﹤0.01%	37
2025 Q3	$2.98K	Hold	99,692	–	–	﹤0.01%	35
2025 Q2	$4.45K	Buy	+99,692	New	+$4.92K	﹤0.01%	32

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VR Advisory Services's ASBPW Position: Q1 2026 in Review

VR Advisory Services held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 99,692 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #40.

VR Advisory Services first reported a position in ASBPW in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.45K in Q2 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

VR Advisory Services held 99,692 shares of Aspire Biopharma Warrant worth $1.66K as of Q1 2026.
VR Advisory Services left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
Aspire Biopharma Warrant made up ﹤0.01% of VR Advisory Services's portfolio in Q1 2026, its #40 holding.
VR Advisory Services first reported a position in Aspire Biopharma Warrant in Q2 2025 and has held it in 4 quarters since.
VR Advisory Services's Aspire Biopharma Warrant position peaked at $4.45K in Q2 2025.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on VR Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.